Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders

References

• Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–569.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582–2590.
   PubMed Web of Science ®Google Scholar
• Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113:5412–5417.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121–1127.
   PubMed Web of Science ®Google Scholar
• Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585–621.
   PubMed Web of Science ®Google Scholar
• Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345:458–460.
   PubMed Web of Science ®Google Scholar
• Serrano M, Lin AW, McCurrach ME, et al. Oncogenic RAS provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88:593–602.
   PubMed Web of Science ®Google Scholar
• Chang BD, Broude EV, Dokmanovic M, et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 1999;59:3761–3767.
   PubMed Web of Science ®Google Scholar
• Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004;432:307–315.
   PubMed Web of Science ®Google Scholar
• Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature. 2005;436:642.
   PubMed Web of Science ®Google Scholar
• Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436:720–724.
   PubMed Web of Science ®Google Scholar
• Braig M, Lee S, Loddenkemper C, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 2005;436:660–665.
   PubMed Web of Science ®Google Scholar
• Di Leonardo A, Linke SP, Clarkin K, et al. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 1994;8:2540–2551.
   PubMed Web of Science ®Google Scholar
• d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003;426:194–198.
   PubMed Web of Science ®Google Scholar
• Herbig U, Jobling WA, Chen BP, et al. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell. 2004;14:501–513.
   PubMed Web of Science ®Google Scholar
• Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005;436:725–730.
   PubMed Web of Science ®Google Scholar
• Brown JP, Wei W, Sedivy JM. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science.1997;277:831–834.
   PubMed Web of Science ®Google Scholar
• Majumder PK, Grisanzio C, O'Connell F, et al. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell. 2008;14:146–155.
   PubMed Web of Science ®Google Scholar
• Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA. 1995;92:9363–9367.
   PubMed Web of Science ®Google Scholar
• Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2010;10:51–57.
   PubMed Web of Science ®Google Scholar
• Collado M, Serrano M. The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer. 2006;6:472–476.
   PubMed Web of Science ®Google Scholar
• Andrulis M, Lehners N, Capper D, et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013;3:862–869.
   PubMed Web of Science ®Google Scholar
• Neben K, Jauch A, Hielscher T, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol. 2013;31:4325–4332.
   PubMed Web of Science ®Google Scholar
• Chang H, Jiang N, Jiang H, et al. CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma. Haematologica. 2010;95:1542–1547.
   PubMed Web of Science ®Google Scholar
• Merz M, Hielscher T, Wagner B, et al. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia. 2014;28:1902–1908.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100:1417–1424.
   PubMed Web of Science ®Google Scholar
• Gray-Schopfer VC, Cheong SC, Chong H, et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16?. Br J Cancer. 2006;95:496–505.
   PubMed Web of Science ®Google Scholar
• Steinbrunn T, Stuhmer T, Gattenlohner S, et al. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood. 2011;117:1998–2004.
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Kuehl M, Lodahl M, et al. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood. 2005;105:317–323.
   PubMed Web of Science ®Google Scholar
• Gartel AL, Tyner AL. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res. 1999;246:280–289.
   PubMed Web of Science ®Google Scholar
• Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400–414.
   PubMed Web of Science ®Google Scholar
• Rowland BD, Peeper DS. KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer. 2006;6:11–23.
   PubMed Web of Science ®Google Scholar
• Fan Y, Chen H, Qiao B, et al. c-Jun NH2-terminal kinase decreases ubiquitination and promotes stabilization of p21(WAF1/CIP1) in K562 cell. Biochem Biophys Res Commun. 2007;355:263–268.
   PubMed Web of Science ®Google Scholar
• Wagner EF, Hleb M, Hanna N, et al. A pivotal role of cyclin D3 and cyclin-dependent kinase inhibitor p27 in the regulation of IL-2-, IL-4-, or IL-10-mediated human B cell proliferation. J Immunol. 1998;161:1123–1131.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Endo H, Chikatsu N, et al. Expression of p21(Cip1/Waf1/Sdi1) and p27(Kip1) cyclin-dependent kinase inhibitors during human hematopoiesis. Blood. 1999;93:4167–4178.
   PubMed Web of Science ®Google Scholar
• Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol. 2003;13:41–47.
   PubMed Web of Science ®Google Scholar
• Zhan F, Colla S, Wu X, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007;109:4995–5001.
   PubMed Web of Science ®Google Scholar
• Carrasco DR, Tonon G, Huang Y, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006;9:313–325.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Attal M, Campion L, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30:1949–1952.
   PubMed Web of Science ®Google Scholar
• Filipits M, Pohl G, Stranzl T, et al. Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma. Clin Cancer Res. 2003;9:820–826.
   PubMed Web of Science ®Google Scholar
• Mangiacavalli S, Pompa A, Ferretti V, et al. The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol. 2017;96:73–80.
   PubMed Web of Science ®Google Scholar
• Billecke L, Murga Penas EM, May AM, et al. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol. 2013;161:87–94.
   PubMed Web of Science ®Google Scholar
• Qu X, Chen L, Qiu H, et al. Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance. Biomed Res Int. 2015;2015:787809.
   PubMed Web of Science ®Google Scholar
• Gire V, Roux P, Wynford-Thomas D, et al. DNA damage checkpoint kinase Chk2 triggers replicative senescence. EMBO J. 2004;23:2554–2563.
   PubMed Web of Science ®Google Scholar
• Coppe JP, Desprez PY, Krtolica A, et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol Mech Dis. 2010;5:99–118.
   PubMed Web of Science ®Google Scholar
• Ruhland MK, Loza AJ, Capietto AH, et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat Comms. 2016;7:11762.
   PubMed Web of Science ®Google Scholar
• Cahu J, Bustany S, Sola B. Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells. Cell Death Dis. 2012;3:e446.
   PubMed Web of Science ®Google Scholar
• Tanabe O, Kawano M, Tanaka H, et al. BSF-2/IL-6 does not augment Ig secretion but stimulates proliferation in myeloma cells. Am J Hematol. 1989;31:258–262.
   PubMed Web of Science ®Google Scholar